Work

P-231 ABBV-383, a BCMA-CD3 bispecific antibody, in relapsed/refractory multiple myeloma: a multicenter, phase 1b dose optimization study with step-up dosing

Year: 2023

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(23)01849-9

Authors: Muhamed Baljevic, Hila Magen, Emma Searle, Ziyi Jin, Elise Strange, Anders Svensson, Shaji Kumar

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4387003664

Cites:

Cited by:

Related to: 10